Obinutuzumab is a glycoengineered antibody that demonstrated significantly higher efficacy over rituximab and other Type I monoclonal antibodies in B-cell malignancies such as CLL. The effect of the glycoengineering improves the binding of monoclonal antibodies with immune cells
